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Background/aim: Thiol status is a good reflector of the cellular redox and have vital roles in various cellular signaling pathways. The
purpose of the study was to investigate thiol status in patients with SARS-CoV-2 infection.
Materials and methods: A total of 587 subjects (517 patients/70 healthy controls) were enrolled in the study.The patients were categorized
into the groups regarding to the severity of disease (mild, moderate, severe, and critical).Thiol status of all groups were compared.
Results: The patients had significantly diminished thiol levels compared to controls. Thiol levels were gradually decreased as the severity
of the disease increased. Logistic regression analyses identified that thiol concentrations were an independent risk factor for the disease
severity in each phase (mild group OR 0.975, 95%CI 0.965-0.986; moderate group, OR 0.964, 95%CI 0.953-0.976; severe group OR
0.953, 95%CI 0.941-0.965; critical group OR 0.947, 95%CI 0.935-0.960).Thiol test exhibited the largest area under the curve at 0.949,
with the highest sensitivity (98.6%) and specificity (80.4%).
Conclusions: Depleted thiol status was observed in SARS-CoV-2 infection. Decline of the thiol levels by degrees while the severity of
infection increased was closely related to the progression of the disease. This outcome highlights that thiols could be an impressible
biomarker for predicting of the severity of COVID-19.
Key words: COVID-19, inflammation, immune response, severity, thiol

1. Introduction
A new variant of coronavirus was found out at the end
of the 2019 [1]. The infection brought on by the novel
causative agent, severe acute respiratory syndrome
coronavirus 2, was broadly accepted as coronavirus
disease-2019 (COVID-19) [1,2]. COVID-19 has been
notified from more than one hundred countries across the
world, culminating in pandemic. The COVID-19 outbreak
constitutes a notable challenge for individuals and society,
as well as health systems and communities [2].
COVID-19 exhibits a wide array of clinical
characterizations from asymptomatic illness to severe lung
disease and/or multiorgan failure [3]. The effectiveness
of the host’s immune response has a very substantial
influence on establishing the clinical manifestations [3]. In
the course of viral infection innate and adaptive immune
cells get involved in immune response [4–7]. Studies have
demonstrated that SARS-CoV-2 is able to effect both the

respiratory epithelial cells and alveolar macrophages [4,5].
Moreover, SARS-CoV-2 has capability to replicate in lung
tissues resulting in activation of innate immune response
and augmentation of cytokines generation [5,6]. It is well
revealed that SARS-CoV-2 triggers a Th1 type immune
response and reduces circulating NK cells and T-cell
subsets [3–7].
Inflammation is a crucial component of functional
immune response [3,8]. It is hard to effectively eliminate
infections in the absence of inflammation [3]. Although,
SARS-CoV2 induces extreme cytokine responses in certain
infected subjects, recognized as a cytokine storm [8,9]. It
can be obviously stated that if there is a deficiency in the
protective immune components including Th1 responses
and cytotoxic CD8 cells, the immune dysregulation occurs
[4]. Immune dysregulation results in a series of mechanisms
that begin with acute inflammation, leading to cytokine
storm, lung damage, and multiple organ failure [4,8,9].
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Protein thiols and low molecular weight thiols
like cysteine, glutathione form plasma thiols [10]. It is
well known that thiols participate in cellular functions
ranging from proliferation, apoptosis to inflammation
and immune response [10,11]. Additionally, thiols are
the main elements of antioxidant defense system [12]. A
peptide thiol, glutathione (GSH), has a protective role in
getting under control the proinflammatory situation in the
lungs [13]. Nuclear factor kappa (NFKB) is a transcription
factor that takes a significant part in the activation of
inflammatory response [13,14]. Lung inflammation may
stimulate the transcription factors like NFKB that regulates
the expression of proinflammatory and antioxidant genes.
GSH downregulates the activity of NFKB [13–15]. This
indicates that the redox status of thiols may be a vital
key in the modulation of the inflammatory responses in
pulmonary tissue.
Several reports have demonstrated the impact of thiol
status in various infections and inflammatory diseases [16].
As thiol status is a good indicator of the cellular redox and
have critical roles in several cellular signaling pathways, in
this study, we aimed to investigate thiol levels in patients
suffering with COVID-19. Until now, there has been no
report regarding thiol status in SARS-CoV-2 infection, so
this study constitutes the first paper in this area.
2. Materials and methods
2.1. Study design
For this prospective study, patients who were suffering
from COVID-19 and admitted to Ankara City Hospital
were included. Ankara City Hospital, which is responsible
for the COVID-19 care assigned by the government, is
one of the main hospitals in Turkey. The study procedure
was set in accordance with the basis of the Helsinki
Declaration and confirmed by the local ethics board (date:
11/11/2020, number: E1/1190/2020). Clinical diagnosis
and classifications were performed in compliance with
the directory of the World Health Organization (WHO)
for COVID-19 and Diagnosis And Treatment Protocol
for COVID-19 Patients (Trial Version 8). Confirmed
cases having a positive RT-PCR detection of the novel
coronavirus nucleic acid and/or imaging characteristics
of COVID-19 were enrolled in the study. Patients having
unconfirmed diagnosis of SARS-CoV-2 infection were
excluded. Healthy individuals having a negative RT-PCR
test results for SARS-CoV-2 represent the control group.
A detailed history was taken from all participants and
all subjects got examined extensively and had routine
blood tests. Epidemiologic characteristics and radiologic
imaging and routine laboratory test results were derived
from electronic medical records.
Venous blood samples were collected from each
participant via venipuncture immediately on admission
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to the hospital within 24 h after diagnosis with SARSCoV-2 infection. Afterward samples were processed by
centrifugation at 1500 g from 10 min. Separated serum
samples were frozen and held at –80 until the analysis was
done. Serum thiol concentrations were determined with
5,-5’-dithiobis-(2-nitrobenzoic) acid (DTNB) according to
the spectrophotometric assay defined by Erel & Neselioglu
[10]. Measurements were made using a Siemens ADVIA
1800 chemistry analyzer (Siemens Healthcare GmbH,
Erlangen, Germany).
2.2. Statistical analysis
Variables were evaluated regarding their distribution
by both visual (histograms, plots) and statistical tests
(the Kolmogorov–Smirnov test and the Shapiro–Wilk
test). Continuous variables were represented as means
and standard deviations or medians and interquartile
ranges when appropriate in respect to their distribution.
Categorical variables were expressed by numbers and
percentages (%). To compare differences among groups a
one-way ANOVA with a Bonferroni post-hoc test and a
Kruskal–Wallis, along with a Dunn’s multiple comparison
post-hoc test was used for analyses. Categorical variables
were evaluated by the chi-square or Fisher’s exact test.
Between-group comparisons (control group vs. patient
group) were applied using Student’s t-test or Mann–
Whitney U test. Correlation analyses were performed
using Pearson’s correlation for normal distributions
and the Spearman’s correlation test for nonnormal
distributions. The optimal cut-off value, sensitivity, and
specificity of thiol test were defined by analysis of receiver
operating characteristic (ROC) curve. Multinomial
logistic regression analysis was conducted to determine
the independent risk factors for the severity of COVID-19.
All the statistical calculations were performed using the
Statistical Package for Social Sciences (SPSS) software
program (v.22; IBM, Armonk, NY, USA) and a P value less
than 0.05 was set statistically significant for all analyses.
3. Results
A total of 517 patients with confirmed SARS-CoV-2
infection were enrolled in the study, among them 200
(38.7%) were female and 317 (61.3%) were male. The
patients were categorized into groups according to the
severity of disease: 172 cases were severe group (90 as
severe and 82 as critical), and 345 cases were non-severe
group (85 as mild and 260 as moderate). The control group
consisted of 70 healthy individuals (44 male/26 female).
The mean age of the patient group was 63.81, and the mean
age of the control group was 41.29. The most prevalent
presenting symptoms were dyspnea, fever, and cough.
Hypertension and chronic lung disease were the main
underlying diseases followed by cardiovascular diseases
and diabetes in severe and critical group. The demographic
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and clinical features of participants with COVID-19 were
summarized in Table 1.
As thiol test results and certain laboratory findings of
the subjects were represented in Table 2 and Figure A; thiol
concentrations were significantly different when compared
synchronously in all 5 groups (one-way ANOVA, P <
0.001). When post-hoc testing was conducted it was found
that thiol levels were significantly lower in all COVID-19
groups than healthy group (P < 0.001, for all). Moreover,
patients in the critical COVID-19 group had the lowest
thiol amounts than the other COVID-19 groups (P < 0.05,
for all). When evaluated based on routine blood tests,
lactate dehydrogenase (LDH) values were significantly
higher in patients in critical group than in other groups (P
< 0.05, for all). Patients had significantly higher D-dimer,
procalcitonin (PCT), C-reactive protein (CRP), ferritin,
troponin I, urea, creatinine and aspartate aminotransferase
(AST), and international normalized ratio (INR) in critical
COVID-19 group than in mild and moderate COVID-19

group and controls (P < 0.001, for all). However, the
patients in severe group had lower D-dimer, PCT, CRP,
ferritin, troponin I, urea, creatinine and AST levels; these
differences were not statistically significant (P > 0.05,
for all). In terms of lymphocyte (LYM) counts, patients
in critical group had the lowest LYM counts in all study
groups. Although patients had higher LYM counts in severe
COVID-19 group than critical group, the differences was
not significantly significant (P > 0.05). The thiol test was
negatively correlated with D-dimer, troponin I, ferritin,
LDH, CRP, LYM, INR, urea, and AST levels (r = –0.52, r =
–0.50, r = –0.50, r = –0.49, r = –0.47, , r = –0.45, r = –0.41,
r = –0.40, r = –0.37, respectively; P < 0.001, for all).
Receiver operating characteristic (ROC) analyses were
performed to assess the value of the thiol test and other
routine blood parameters to discern the patients with
SARS-CoV-2 infection from healthy individuals. As shown
in Figure B and Table 3, the area under curve (AUC) for
the thiol test (0.949) was greater than the other parameters.

Table 1. Clinical characteristics of patients with COVID-19.

Age, mean ± SD

Mild COVID-19 cases Moderate COVID-19 cases Severe COVID-19 cases Critical COVID-19 cases
P*
n = 85
n = 260
n = 90
n = 82
52.1 ± 14.16
63.34 ± 14.54
68.71 ± 13.48
71.23 ± 12.84
< 0.05

Sex

< 0.05

Male

41 (48.1)

157 (60.4)

64 (72.6)

55 (69.3)

Female

44 (51.9)

103 (39.6)

26 (27.4)

27 (30.7)

Fever

13 (16.5)

41 (15.8)

20 (23.8)

15 (20)

> 0.05

Cough

17 (21.5)

42 (16.2)

21 (25)

8 (10.7)

> 0.05

Dyspnea

11 (13.9)

63 (24.2)

17 (20.2)

25 (33.3)

<0.05

Fatigue

10 (12.7)

34 (13.1)

11 (13.1)

15 (20)

> 0.05

Nausea and vomiting 8 (10.1)

15 (13)

3 (3.6)

5 (6.7)

> 0.05

Myalgia, arthralgia

5 (6.3)

17 (6.5)

3 (3.6)

3 (4)

> 0.05

Diarrhea

3 (3.8)

8 (3.1)

1 (1.2)

-

> 0.05

Headache

3 (3.8)

5 (1.9)

2 (2.4)

-

> 0.05

13 (16.5)

38 (14.6)

17 (20.2)

13 (17.3)

> 0.05

Hypertension
15 (19)
Cardiovascular
4 (5.1)
disease
Chronic lung disease 9 (11.4)

50 (19.2)

28 (33.3)

25 (33.3)

< 0.05

20 (7.7)

18 (21.4)

17 (22.7)

< 0.05

52 (20)

25 (29.7)

23 (30.6)

> 0.05

Malignancy
1 (1.3)
Chronic kidney
disease
Neurologic disorders 2 (2.5)

5 (1.9)

3 (3.6)

4 (5.3)

> 0.05

3 (1.9)

3 (3.6)

7 (9.3)

< 0.05

12 (4.6)

10 (12)

5 (6.6)

> 0.05

Signs and symptoms

Comorbidities
Diabetes

Categorical variables were expressed as numbers (n) and percentages (%). P* value < 0.05 considered statistically significant.
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Table 2. Laboratory findings of individuals in study groups.

Thiol, µmol/L

Control group
Mild group
Moderate group
Severe group
(n = 70)
(n = 85)
(n = 260)
(n = 90)
419.76 ± 55.88 b,c,d,e 341.13 ± 73.91a,c,d,e 262.02 ± 66.87 a,b,d,e 203.33±70.86 a,b,c,e

Critical group
(n = 82)
166.48 ± 79.4 a,b,c,d

LDH, U/L

199 (45)

443 (307)

Troponin I, ng/L

2.5 (1.5) c,d,e

INR

1.00 (0.03) b,c,d,e

D-dimer, mg/L

0.315 (0.23)

PCT, µg/L

0.03 (0.01)

Ferritin, µg/L

38 (188) b,c,d,e

158 (233) a,c,d,e

288.5 (446) a,b,d,e

616.5 (695) a,b,c

674 (890) a,b,c

< 0.001

LYM, 109/L

1.90 (0.84) c,d,e

1.80 (0.82) c,d,e

1.03 (0.90) a,b,d,e

0.82 (0.45) a,b,c

0.60 (0.45) a,b,c

< 0.001

PLT, 109/L

261 (104)

269 (207) e

297 (191) e

265 (146)

234 (124) b,c

> 0.05

CRP, g/L

0.003 (0.006)

Urea, mg/dL

26 (9) b,c,d,e

CRE, mg/dL

0.72 (0.15)

ALT, U/L

19 (17)

AST U/L

16 (8) b,c,d,e

Parameters

244(130)

b,c,d,e

2.4 (0.6) c,d,e
c,d,e

c,d,e

c,d,e

b,c,d,e

a,b,d,e

351 (147)

a,b,c,e

a,b,c,d

< 0.001*
< 0.001

4.74 (7.6) a,b,d,e

9.5 (28.4) a,b,c

19.5 (56) a,b,c

< 0.001

1.04 (0.11) a,c,d,e

1.09 (0.15) a,b,d,e

1.16 (0.16) a,b,c

1.17 (0.2) a,b,c

< 0.001

0.325 (0.30)

0.790 (0.89)

1.21 (1.56)

a,b,c

1.230 (2.4) a,b,c

< 0.001

0.10 (0.17)

a,b,c

0.19 (0.59)

0.03 (0.03)

c,d,e

c,d,e

0.006 (0.013)
34 (20) a,c,d,e

b,c,d,e

292 (125)

a,c,d,e

P value

0.80 (0.29)
44 (37)

a

27 (19) a,d,e

c,d,e

0.04 (0.07)

a,b,d,e

a,b,d,e

0.020 (0.044)
43 (27) a,b,e

a,e

0.87 (0.34)
43 (42)

a

29 (23) a,e

a,b,d,e

0.040(0.08)

a,b,c

52 (35) a,b
a,e

0.92 (0.57)
36 (52)

a

36 (29) a,b

a,b,c

0.075 (0.11)

a,b,c

64 (66) a,b,c
a

1.03 (1.03)
33 (27)

a

49 (41) a,b,c

< 0.001

< 0.001
< 0.001

a,b,c

< 0.001
< 0.001
< 0.001

Values are expressed as mean ± SD and median (interquartile range). P value*, one-way analysis of variance [ANOVA]; P value, Kruskal–
Wallis. a Statistically significant difference between the control group vs. other groups; b Statistically significant difference between
mild group vs. other groups; c Statistically significant difference between moderate group vs. other groups; d Statistically significant
difference between severe group vs. other groups; e Statistically significant difference between critical group vs. other groups; LDH
lactate dehydrogenase; INR, international normalized ratio; LYM, lymphocyte count; PLT, platelet count; CRP, C-reactive protein; PCT,
procalcitonin; CRE, creatinine; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Figure a. the alteration of thiol levels via the severity of COVID-19 (x̄ ± σx̅), b. ROC curve of the thiol test predicting COVID-19.
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The optimal cut-off level for thiol test was 323 µmol/L,
the sensitivity was 0.986, and the specificity was 0.804.
Multinomial logistic regression analysis was applied to
identify the independent risk predictors for the severity
of COVID-19. Thiol and ferritin levels were independent
risk factors for the infection severity with each step of
disease with the likelihood ratios presented in Table 4.
Nevertheless, the risk of D-dimer and LYM were partial
and other variables were unclear. Multivariate logistic
regression analysis was performed to interpret the disease

severity dependent variable using thiol and age independent
variables. As a result of the analysis, a significant regression
model was found [F (2.354) = 243.3, P < 0.001]. Overall,
58% of the variance in the dependent variable was explained
by the independent variables. Accordingly, the independent
variable thiol predicts the severity of the disease negatively
and significantly (β = –0.61, t (354) = –13.52, P < 0.001, pr2
= 0.34). In addition, age, the independent variable, predicts
the severity of the disease positively and significantly (β =
0.22, t (354) = 4.83, P < 0.001, pr2 = 0.062).

Table 3. The value of the studied parameters in predicting cases with COVID-19.
Variables
Thiol, µmol/L
Ferritin, µg/L
D-dimer, mg/L
LYM, 109/L
CRP, g/L
LDH, U/L
INR
PCT, µg/L
Troponin I, ng/L

AUC (95% CI)
0.949
0.937
0.829
0.806
0.814
0.881
0.843
0.706
0.739

Std. error a
0.009
0.012
0.023
0.021
0.024
0.019
0.022
0.021
0.025

Asymptotic sig. b
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

Asymptotic 95% confidence interval
0.931–0.968
0.914–0.960
0.784–0.874
0.765–0.847
0.767–0.860
0.844–0.918
0.801–0.885
0.665–0.747
0.691–0.787

CRP, C-reactive protein; PCT, procalcitonin; LYM, lymphocyte count; LDH, lactate dehydrogenase; INR, international normalized
ratio; AUC, are under curve. The test result variables have at least one tie between the positive actual state group and the negative actual
state group.
Table 4. Multinomial logistic regression analysis.
Multinomial logistic regression models
Mild
Parameters

OR (95% Cl)

Moderate
P value

P value

OR (95% Cl)

Critical
P value

OR (95% Cl)

P value

D-dimer, mg/L

NS

0.274

LYM, 109/L

NS

0.794

PLT, 109/L

NS

0.714

0.964
0.953
< 0.001*
(0.953–0.976)
(0.941–0.965)
1.021
1.021
< 0.001*
(1.012–1.031)
(1.012–1.030)
9.895
10.054
0.002*
(2.274–43.051)
(2.303–43.882)
0.187
NS
0.065
(0.06–0.535)
NS
0.922
NS

0.520

0.947
(0.935–0.960)
1.021
(1.012–1.030)
10.733
(2.455–46.868)
0.062
(0.015–0.258)
NS

LDH, U/L

NS

0.796

NS

0.807

NS

0.600

NS

0.105

Troponin I, ng/L NS

0.177

NS

0.146

NS

0.131

NS

0.124

CRP, g/L

NS

0.419

NS

0.370

NS

0.259

NS

0.272

INR

NS

0.339

NS

0.311

NS

0.333

NS

0.402

PCT, µg/L

NS

0.038

NS

0.222

NS

0.541

NS

0.970

Thiol, µmol/L
Ferritin, µg/L

0.975
< 0.001*
(0.965–0.986)
1.021
< 0.001*
(1.011–1.030)

OR (95% Cl)

Severe

< 0.001*
< 0.001*
0.002*
0.002*

< 0.001*
< 0.001*
0.002*
< 0.001*
0.074

OR: odds ratio; NS: not significant.
LDH, lactate dehydrogenase; INR, international normalized ratio; LYM, lymphocyte count; PLT, platelet count; CRP, C‐reactive protein;
PCT, procalcitonin; CRE, creatinine; ALT, alanine aminotransferase; AST, aspartate aminotransferase
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4. Discussion
The SARS-CoV-2 pandemic has expanded throughout
the worldwide and generated a threat for societies,
governments, and individuals [2]. COVID-19 displays
a broad spectrum of clinical manifestations from
asymptomatic to mild and moderate and eventually critical
condition [3]. In the course of SARS-CoV-2 infection,
replication of virus, immune and inflammatory responses
are dynamic factors that can alter rapidly and lead various
outcomes [4]. During viral infections both innate and
adaptive systems concurrently take part in viral responses
[7]. Production of several proinflammatory cytokines,
activation of T cell and its subgroups are fundamental to
take control the viral replication [6].
Thiols (-SH containing compounds) exist in protein
motifs and function in enzyme modulation, signaling,
inflammation, and immune response [10,11]. As the thiol
redox system is vital, it changes in response to occurrence
of disease, environmental factors, and several other
conditions [16]. Alterations in the thiol network have
pointed out a broad range of disorders. To the best of
our knowledge, no prior report related to thiol status in
COVID-19 has been published.
Our results showed that thiol levels were lower in
patients suffering from SARS-CoV-2 infection than
controls. This data may suggest that thiols were used
and depleted during the infection. There is a growing
evidence that thiols have a crucial point in antioxidant
defense, inflammation, and immune response [10–16].
Thus, thiols could be consumed during the SARS-CoV-2
infection which is related to a hyperinflammation status
called a cytokine storm. The ROC analysis revealed
that the thiol test provided an excellent discrimination
between patients with COVID-19 and controls with an
AUC of 0.949. Furthermore, it was observed that thiol
levels decreased as the severity of the disease increased.
In multinomial logistic regression analysis, thiols were
found to be an independent risk factor for the severity of
COVID-19. In addition, multivariate analysis revealed that
the contribution of thiol in predicting the severity of the
disease is considerably higher than age. These outcomes
indicated that thiol status has a crucial position in the
development and progression of COVID-19. Elevated CRP,
PCT, and ferritin markers of inflammation were obtained
in patients with COVID-19, when compared to the
healthy controls. Also, the level of inflammation markers
enhanced as the severity of the disease increases. This
gradual increase of inflammation markers coincides with
the gradual decrease of thiol levels. In addition, there were
strong negative relationships between thiol concentrations
and CRP, PCT and ferritin, markers of inflammation.
Obtained data reflected that thiols are a notable key in
inflammatory response to metabolic characteristics in
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SARS-CoV-2 infection. D-dimer levels that increased
with the severity of the disease exhibited the activation
of coagulation in severe and critical COVID-19. There
were intense negative correlations between thiol amounts
and D-dimer levels. Previous reports demonstrated
that sulfhydryl groups on platelet surface have a role
in platelet responses [17]. Platelets are known to have
primary potential contributions in hypercoagulation and
thrombotic events in COVID-19 [18,19]. This information
suggests that there may be a relationship between depleted
thiol levels and hypercoagulation in severe cases of SARSCoV-2 infection.
It was recognized that the variability in the course
of the disease is due to a disequilibrium between
proinflammatory and antiinflammatory factors in the
lung tissue [4]. Primarily, acute inflammation follows
the respiratory tract infection. In certain individuals the
immune system causes viral disruption and bring down
the inflammation while the others produce cytokine storm
and hyperinflammation that results in multiorgan injury
[20]. Glutathione, which is a thiol containing tripeptide,
modulates the angiotensin converting enzyme (ACE)
expression and activity. The SARS-CoV-2 infected cells
results in inhibition of ACE2 activity and diminished
ACE2 expression [21]. ACE activity induces oxidative
stress, inflammation, and apoptosis, whereas ACE2
leads antiinflammatory, antioxidative, and antiapoptotic
effects. The imbalance between ACE and ACE2 activities
ends in hyperinflammation and ARDS [21]. Thus, GSH
and other thiols may provide a protective role against
augmented inflammation in SARS-CoV-2 infection based
on ACE-ACE2 system. The NF-κB (nuclear factor kappa
B), signaling pathway is participated in the development
of the conventional pathway of inflammation [22]. GSH
inhibits the activation of NF-kB and therefore maintains
the cytokine storm under control [21]. A recent study
evaluated the effects of using glutathione in the 2 patients
with COVID-19 [23]. Glutathione was found to be effective
in remission of respiratory symptoms [23].
N-acetylcysteine (NAC) is both thiol and one of the
components of GSH synthesis [21]. There have been
several clinical studies examining the use of NAC in
respiratory diseases [24,25]. NAC has been demonstrated
to represent protective effects in ARDS [24]. Furthermore,
NAC induces the of nuclear factor erythroid 2-related
factor 2 (Nrf2), which modulates antioxidant enzyme
genes and downregulates inflammation [24].
5. Conclusion
Thiol status is depleted in COVID-19. The decrease
of the thiol levels reflects the gradual increase in the
severity of SARS-CoV-2 infection. Intense associations
between thiol amounts and inflammatory markers
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support the significant role of thiols in immune and
inflammatory responses. These data underline that thiols
can be a sensitive indicator for predicting the severity of
COVID-19. Thiol based agents such as NAC, lipoic acid,
and GSH, blocking the NF-kB signaling, are promising for
the novel therapy approaches against cytokine storm and
hyperinflammation in COVID-19.
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